Literature DB >> 1911206

A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas.

P W Johnson1, P I Thompson, M T Seymour, N P Deasy, R C Thuraisingham, M L Slevin, P F Wrigley.   

Abstract

The combination of high-dose folinic acid with 5-fluorouracil has shown improved response rates in several trials in advanced colorectal carcinoma. This however is at the expense of increased toxicity: regimens using weekly bolus injections produce diarrhoea in most patients and occasional toxic deaths from this, whilst those using daily injections for one week in four report both diarrhoea and severe oral mucositis. Both types of regimen have significant rates of myelosuppression. A recent report described a different schedule of 5-fluorouracil and folinic acid, which appeared better tolerated but equally active (De Gramont et al., 1988). Here we report results using the same programme, in 64 patients with advanced adenocarcinomas. (Forty three colorectal, ten gastric, six pancreatic and five of unknown primary.) Patients received 200 mg m-2 folinic acid by infusion over 2 h followed by an IV bolus of 5-fluorouracil 400 mg m-2 then an infusion of 5-fluorouracil 400 mg m-2 over 22 h. This was repeated over the next 24 h. The schedule was given every 2 weeks for a total of six to 12 courses depending upon the response. The overall response rate was 26% in 62 evaluable patients. No toxicity greater than WHO Grade II occurred. Diarrhoea and mucositis did occur in around 10% of treatments but were not troublesome. No febrile neutropenic episodes were seen. Despite previous reports which described only modest activity for this combination against stomach cancers, this regimen demonstrates low toxicity but retains good activity in the palliative treatment of both gastric and colonic adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911206      PMCID: PMC1977639          DOI: 10.1038/bjc.1991.358

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.

Authors:  N Petrelli; H O Douglass; L Herrera; D Russell; D M Stablein; H W Bruckner; R J Mayer; R Schinella; M D Green; F M Muggia
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

Review 2.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

Authors:  M A Poon; M J O'Connell; C G Moertel; H S Wieand; S A Cullinan; L K Everson; J E Krook; J A Mailliard; J A Laurie; L K Tschetter
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

3.  Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma.

Authors:  P Seifert; L H Baker; M L Reed; V K Vaitkevicius
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

4.  High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.

Authors:  A De Gramont; M Krulik; J Cady; B Lagadec; J E Maisani; J P Loiseau; J D Grange; G Gonzalez-Canali; B Demuynck; C Louvet
Journal:  Eur J Cancer Clin Oncol       Date:  1988-09

5.  An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).

Authors:  H O Douglass; P T Lavin; A Goudsmit; D J Klaassen; A R Paul
Journal:  J Clin Oncol       Date:  1984-12       Impact factor: 44.544

6.  Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.

Authors:  D Machover; E Goldschmidt; P Chollet; G Metzger; J Zittoun; J Marquet; J M Vandenbulcke; J L Misset; L Schwarzenberg; J B Fourtillan
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

7.  A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.

Authors:  J J Lokich; J D Ahlgren; J J Gullo; J A Philips; J G Fryer
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

8.  A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.

Authors:  C Erlichman; S Fine; A Wong; T Elhakim
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

9.  A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma.

Authors:  S G Arbuck; H O Douglass; F Trave; S Milliron; M Baroni; H Nava; L J Emrich; Y M Rustum
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

Review 10.  Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer.

Authors:  S G Arbuck
Journal:  Cancer       Date:  1989-03-15       Impact factor: 6.860

View more
  14 in total

Review 1.  Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J C de Graaf; J L Coenen; J R Brouwers
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Oncology.

Authors:  J S Malpas
Journal:  Postgrad Med J       Date:  1993-02       Impact factor: 2.401

Review 3.  Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J L Coenen; J C De Graaf; J R Brouwers
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

4.  Chemotherapy for advanced gastric cancer: slow but further progress.

Authors:  Yeul Hong Kim
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

5.  High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma.

Authors:  M S Highley; M E Hill; N Ziras; N Samandas; R C Mason; W Owen; J Dussek; S Barker; P G Harper
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

6.  Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

Authors:  M J Mackean; J Cassidy; D I Jodrell; J Paul; N S Reed; P A Canney; H Yosef; T Habeshaw; A G Robertson; A McInnes; C J Twelves
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

7.  Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?

Authors:  D I Jodrell; L S Murray; N S Reed; P A Canney; S B Kaye; J Cassidy
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

8.  High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.

Authors:  C L Hanna; F E McKinna; L B Williams; D Morrey; M Adams; M D Mason; T S Maughan
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

9.  Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.

Authors:  M T Seymour; P W Johnson; M R Hall; P F Wrigley; M L Slevin
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

10.  A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases.

Authors:  H W Warren; J H Anderson; P O'Gorman; E Kane; D J Kerr; T G Cooke; C S McArdle
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.